https://www.fool.com/earnings/call-transcripts/2024/07/18/novartis-ag-nvs-q2-2024-earnings-call-transcript/?source=iedfolrf0000001
Jul 18, 2024 - NVS earnings call for the period ending June 30, 2024.
0
fool:1368314776539150196
0
https://www.zacks.com/stock/news/2299950/is-main-street-capital-main-stock-outpacing-its-finance-peers-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2299950
Jul 11, 2024 - Here is how Main Street Capital (MAIN) and Aegon NV (AEG) have performed compared to their sector so far this year.
zc:4232871797410315590
0
https://www.zacks.com/stock/news/2293892/fda-accepts-ionis-ions-nda-for-rare-disease-drug-olezarsen?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2293892
Jun 26, 2024 - The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
zc:4357553372712245581
0
https://www.zacks.com/stock/news/2290616/ionis-ions-expands-licensing-deal-with-otsuka-for-hae-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2290616
Jun 19, 2024 - Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
zc:6797958643560595510
0
https://www.zacks.com/stock/news/2284645/why-novartis-nvs-is-a-top-value-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2284645
Jun 06, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zc:2876920252085029256
0
https://www.zacks.com/stock/news/2283315/why-novartis-nvs-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2283315
Jun 04, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zc:5273589266395918827
0
https://www.zacks.com/stock/news/2283248/is-asm-international-asmiy-stock-outpacing-its-computer-and-technology-peers-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2283248
Jun 04, 2024 - Here is how ASM International NV (ASMIY) and Celestica (CLS) have performed compared to their sector so far this year.
zc:-3071510626179031064
0
https://seekingalpha.com/article/4697234-novartis-ag-nvs-investor-event-asco-conference-call-transcript?source=feed_sector_transcripts
Jun 03, 2024 -
0
sa:4420423602686121964
0
https://www.zacks.com/stock/news/2282326/novartis-nvs-reports-positive-long-term-data-on-csu-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2282326
May 31, 2024 - Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
zc:979857464232454594
0
https://seekingalpha.com/news/4111993-novartis-reports-positive-phase-3-data-for-remibrutinib-for-chronic-hives?source=feed_sector_healthcare
May 31, 2024 - Novartis (NVS) reported positive Phase 3 data for its autoimmune drug remibrutinib in the treatment of chronic spontaneous urticaria, or hives. Read more here.
0
sa:-7773635763694722512
0